# Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT00113347** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Docetaxel
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT00113347
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113347, "Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00113347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*